ACAD Share Price Performance
US$0
-16.18 (-100.00%)
Price US$0
Fair ValueUS$29.32
Share Pricen/a
Shareholders Shouldn’t Be Too Comfortable With ACADIA Pharmaceuticals' (NASDAQ:ACAD) Strong Earnings
Nov 13
ACADIA Pharmaceuticals Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 98 Fair Values set on narratives written by author
ACAD Community Narratives
AN
Fair Value US$29.32 19.6% undervalued intrinsic discount
Global Outreach And Pipeline Programs Will Expand CNS Markets
0users have liked this narrative
0users have commented on this narrative
48users have followed this narrative
AN
Fair Value US$40 41.1% undervalued intrinsic discount
Secular Trends And Pipeline Expansion Will Drive CNS Therapy Adoption
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$18.12 30.0% overvalued intrinsic discount
Medicare Negotiations And Patent Cliffs Will Stifle Revenues
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Global Outreach And Pipeline Programs Will Expand CNS Markets
Key Takeaways Expanding product demand, strong pipeline progress, and strategic outreach are broadening the patient base and diversifying revenue streams, reducing reliance on single products. Favorable regulatory trends and industry consolidation are enabling faster market access and unlocking new partnership and growth opportunities.Read more
0users have liked this narrative
0users have commented on this narrative
48users have followed this narrative
AN
US$29.32
19.6% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
11.16% p.a.
Profit Margin
21%
Future PE
21.25x
Share price in 2028
US$35.51
Secular Trends And Pipeline Expansion Will Drive CNS Therapy Adoption
Key Takeaways Accelerated international growth and stronger than expected product adoption position ACADIA for substantial revenue and margin expansion across markets. Robust R&D pipeline, strategic financial management, and favorable demographic trends create opportunities for high-return pipeline growth and sustained earnings increases.Read more
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$40
41.1% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
16.66% p.a.
Profit Margin
38.64%
Future PE
13.63x
Share price in 2028
US$48.45
Medicare Negotiations And Patent Cliffs Will Stifle Revenues
Key Takeaways Reliance on a narrow product portfolio and vulnerability to pricing constraints threaten long-term revenue and margin stability. Regulatory, operational, and competitive pressures pose significant risks to growth, innovation, and future market share.Read more
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
US$18.12
30.0% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
8.45% p.a.
Profit Margin
4.4%
Future PE
67.58x
Share price in 2028
US$21.96
Recently Updated Narratives
AN
Global Outreach And Pipeline Programs Will Expand CNS Markets
Fair Value: US$29.32 19.6% undervalued intrinsic discount
48 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Secular Trends And Pipeline Expansion Will Drive CNS Therapy Adoption
Fair Value: US$40 41.1% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Medicare Negotiations And Patent Cliffs Will Stifle Revenues
Fair Value: US$18.12 30.0% overvalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
ACADIA Pharmaceuticals Inc. Key Details
About ACAD
- Founded
- 1993
- Employees
- 654
- CEO
- WebsiteView website
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer’s disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
